


PHARMACEUTICAL 2022

OMEROS CORP Rank 3 of 475







PHARMACEUTICAL 2022

OMEROS CORP Rank 3 of 475



The relative strengths and weaknesses of OMEROS CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OMEROS CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 809% points. The greatest weakness of OMEROS CORP is the variable Revenues, reducing the Economic Capital Ratio by 131% points.

The company's Economic Capital Ratio, given in the ranking table, is 506%, being 783% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	247,889
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	51,789
Liabilities, Non-Current	0
Other Assets	171,379
Other Compr. Net Income	0
Other Expenses	19,669
Other Liabilities	0
Other Net Income	387,521
Property and Equipment	0
Research and Development	118,775
Revenues	0
Selling, General and Administrative Expense	54,842

Output Variable	Value in 1000 USD
Assets	419,268
Liabilities	51,789
Expenses	193,286
Stockholders Equity	367,479
Net Income	194,235
Comprehensive Net Income	194,235
Economic Capital Ratio	506%